Accéder au contenu
Merck
Toutes les photos(2)

Documents

855675P

Avanti

16:0 Lyso PC

Avanti Research™ - A Croda Brand

Synonyme(s) :

1-hexadecanoyl-sn-glycero-3-phosphocholine; PC(16:0/0:0)

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C24H50NO7P
Numéro CAS:
17364-16-8
Poids moléculaire :
495.63
Code UNSPSC :
51191904
Nomenclature NACRES :
NA.25

Description

1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine

Pureté

>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)

Forme

powder

Conditionnement

pkg of 1 × 1 g (855675P-1g)
pkg of 1 × 200 mg (855675P-200mg)
pkg of 1 × 25 mg (855675P-25mg)
pkg of 1 × 500 mg (855675P-500mg)

Fabricant/nom de marque

Avanti Research™ - A Croda Brand

Conditions d'expédition

dry ice

Température de stockage

−20°C

Chaîne SMILES 

O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COC(CCCCCCCCCCCCCCC)=O

InChI

1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m1/s1

Clé InChI

ASWBNKHCZGQVJV-HSZRJFAPSA-N

Catégories apparentées

Application


  • Microbubble-Mediated Drug Delivery: The role of 16:0 Lyso PC in the development of microbubble technologies for drug delivery systems emphasizes its potential in pharmaceutical formulations, enhancing the efficiency of targeted therapy applications, particularly in cancer treatment (Aron et al., 2019).

  • Photodynamic Therapy for Glioma: Research involving 16:0 Lyso PC in the context of biohybrid systems for light-activatable treatments showcases its application in medical therapies, particularly for treating challenging conditions like glioma through photodynamic therapy, underlining its potential in enhancing clinical outcomes (Inglut et al., 2019).

Conditionnement

20 mL Clear Glass Screw Cap Vial (855675P-1g)
20 mL Clear Glass Screw Cap Vial (855675P-500mg)
5 mL Amber Glass Screw Cap Vial (855675P-200mg)
5 mL Amber Glass Screw Cap Vial (855675P-25mg)

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Souvent commandé avec ce produit

Réf. du produit
Description
Tarif

840035P

18:1 PS (DOPS), Avanti Research™ - A Croda Brand

845875P

18:1 Lyso PC, Avanti Research™ - A Croda Brand

850355P

16:0 PC (DPPC), Avanti Research™ - A Croda Brand

850365C

18:0 PC (DSPC), Avanti Research™ - A Croda Brand

850375P

18:1 (Δ9-Cis) PC (DOPC), Avanti Research™ - A Croda Brand

850725P

18:1 (Δ9-Cis) PE (DOPE), Avanti Research™ - A Croda Brand

855575P

14:0 Lyso PC, 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine, powder

855775P

18:0 Lyso PC, Avanti Research™ - A Croda Brand

855800P

24:0 Lyso PC, 1-lignoceroyl-2-hydroxy-sn-glycero-3-phosphocholine, powder

858143P

18:1 Lyso PS, Avanti Research™ - A Croda Brand

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 10

1 of 10

2-16:0 Lyso PC Avanti Research™ - A Croda Brand

Avanti

855674P

2-16:0 Lyso PC

17:0 Lyso PC Avanti Research™ - A Croda Brand

Avanti

855676P

17:0 Lyso PC

18:1 Lyso PC 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine, chloroform

Avanti

845875C

18:1 Lyso PC

16:0 Lyso PG 1-palmitoyl-2-hydroxy-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt), powder

Avanti

858122P

16:0 Lyso PG

16:0 lyso PC-d49 powder

Avanti

870308P

16:0 lyso PC-d49

2-18:0 Lyso PC Avanti Research™ - A Croda Brand 855774P, powder

Avanti

855774P

2-18:0 Lyso PC

16:0 Lyso PI 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphoinositol (ammonium salt), powder

Avanti

850102P

16:0 Lyso PI

18:0 Lyso PE 1-Stearoyl-2-Hydroxy-sn-Glycero-3-Phosphoethanolamine, powder

Avanti

856715P

18:0 Lyso PE

18:1 Lyso PS Avanti Research™ - A Croda Brand

Avanti

858143P

18:1 Lyso PS

Egg Lyso PC Avanti Research™ - A Croda Brand 830071P, powder

Avanti

830071P

Egg Lyso PC

Takafumi Enomoto et al.
Langmuir : the ACS journal of surfaces and colloids, 34(3), 750-755 (2017-10-06)
A major goal of synthetic biology is the development of rational methodologies to construct self-assembling non-natural membranes, which could enable the efficient fabrication of artificial cellular systems from purely synthetic components. However, spatiotemporal control of artificial membrane formation remains both
Xinyuan Li et al.
Redox biology, 28, 101373-101373 (2019-11-16)
It has been shown that anti-inflammatory cytokines interleukin-35 (IL-35) and IL-10 could inhibit acute endothelial cell (EC) activation, however, it remains unknown if and by what pathways IL-35 and IL-10 could block atherogenic lipid lysophosphatidylcholine (LPC)-induced sustained EC activation; and
Caius G Radu et al.
Proceedings of the National Academy of Sciences of the United States of America, 101(1), 245-250 (2003-12-19)
G2A is an immunoregulatory G protein-coupled receptor predominantly expressed in lymphocytes and macrophages. Ectopic overexpression studies have implicated G2A as a receptor for the bioactive lysophospholipid, lysophosphatidylcholine (LPC). However, the functional consequences of LPC-G2A interaction at physiological levels of receptor
Li V Yang et al.
Blood, 105(3), 1127-1134 (2004-09-24)
G2A is a G-protein-coupled receptor (GPCR) involved in immune regulation. Previous studies have shown that lysophosphatidylcholine (LPC), a bioactive lipid associated with atherosclerosis and autoimmunity, acts through G2A to induce diverse biologic effects. Production of LPC during cell apoptosis serves
Yoko Shima et al.
The Journal of biological chemistry, 295(20), 6983-6991 (2020-04-10)
Newly synthesized major histocompatibility complex (MHC) class I proteins are stabilized in the endoplasmic reticulum (ER) by binding 8-10-mer-long self-peptide antigens that are provided by transporter associated with antigen processing (TAP). These MHC class I:peptide complexes then exit the ER
Afficher tous les articles scientifiques apparentés

Articles

Critical Micelle Concentrations (CMCs) - Avanti® Polar Lipids

The critical micelle concentration (CMC) can be approximately defined as the lipid monomer concentration at which appreciable amounts (>5% of total) of micellar aggregates first begin to appear in the equilibrium: nM1<=>Mn

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique